As of September 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $175.4 million with a projected cash runway into the fourth quarter of 2026. Cash includes the $65.0 million net proceeds from the Company’s July 2025 common stock public offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia
- Larimar Therapeutics Reports Promising Clinical Data Update
- 3 Best Stocks to Buy Now, 10/6/2025, According to Top Analysts
- Buy Rating for Larimar Therapeutics: Promising Efficacy of Nomla in Friedreich’s Ataxia Amidst Anaphylaxis Concerns
- Larimar Therapeutics price target lowered to $21 from $26 at Oppenheimer